Latest medullary thyroid cancer Stories
Papillary thyroid cancer accounts for the majority of all thyroid malignancies, which primarily impact women.
A mutant gene long thought to accelerate tumor growth in thyroid cancer patients actually inhibits the spread of malignant cells, showing promise for novel cancer therapies, a Mayo Clinic study has found.
Vandetanib is first drug approved for medullary thyroid cancer SILVER SPRING, Md., April 6, 2011 /PRNewswire-USNewswire/ -- The U.S.
Positron emission tomography (PET) can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent.
Variations of a gene are associated with a type of tumor that forms within the adrenal gland, and were found in an age group uncommon for these types of tumors.
WILMINGTON, Del., Dec.
LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001).
- Sleep; the state or condition of being asleep.